Citations

Clear

626 citation(s) found for "Mehta, SH".

Management and Outcomes of Pulmonary Embolism in Women of Reproductive Age Admitted to Urban Versus Rural Areas Compared to Men
Bansal, Mridul , Mehta, Aryan , Ahmad, Khansa , Bortnick, Anna E. , Abbott, J. Dawn , Vallabhajosyula, Saraschandra, Vallabhajosyula, Saraschandra , Dawn Abbott, J , Vallabhajosyula, Saraschandra , Ahmad, Khansa , Nagaraja, Vinayak , Hyder, Omar N.

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 11, 2024 | Volume: 105 | Issue: 1 | Pages: 193-199

10.1002/ccd.31344 | PMID 39659102 Get It

ABSTRACT There are limited and conflicting data on sex and urban‐rural disparities in outcomes of patients with pulmonary embolism (PE) in the reproductive age group. Our object was to assess sex disparities in the reproductive age group cohort. All adult non‐elective admissions in the reproductive age group (18−49 years) with a primary diagnosis of PE and with no missing sex/age data were identified using the National Inpatient Sample. Females and males were stratified into rural and urban location based on hospital information. Outcomes of interest included in‐hospital mortality, complication rates, variations in management, total hospitalization costs, and length of stay. During 01/01/2016 to 12/31/2020, 180,898 PE admissions aged 18−49 years were identified (rural—12,319 [6.8%]). Females comprised 54.8% and 55.1% of the rural and urban cohorts, respectively. Overall, compared to males, females in urban and rural regions had largely comparable rates of definitive PE interventions, except lower rates of catheter directed therapy (4.7 vs. 3.6%, p < 0.001) in females admitted to urban hospitals. Despite younger age, higher comorbidity, and lower utilization of PE interventions, females in both regions had similar unadjusted in‐hospital mortality (rural 1.1% vs. 1.0%; p = 0.93 and urban 1.8% vs. 1.7%; p = 0.78) and hospitalization costs compared to males. In conclusion, females of reproductive age group had comparable in‐hospital outcomes to males in both urban and rural areas. Females in urban areas had lower utilization of advanced PE interventions, potentially indicating selective management strategies in different settings.
Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
McLaughlin, Eric , Lingamaneni, Prasanth , Cao, Miao , Chang, Tiffany , Ganesan, Nivetha, Luu, Binh, Mehta-Shah, Neha, Allen, Pamela B. , Paulino, Darina, Adams, Brittany , Wang, Jie , Feng, Amber , Marchi, Enrica , Gutierrez, Marc , Frosch, Zachary AK , Sklarz, Tammarah , Sethi, Tarsheen , Beaven, Anne , Haverkos, Bradley , Treitman, Rachel, Stevens, Patrick , Mishra, Anjali , Hampel, Paul J. , Brammer, Jonathan E. , Braunstein, Zachary , Barta, Stefan K , Luu, Binh, Mehta–Shah, Neha , Shree, Tanaya , Watkins, Marcus P. , Zain, Jasmine , Roberts, Nathan, Wilcox, Ryan A. , Foss, Francine M. , Stuver, Robert

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 982-982

10.1182/blood-2024-194242 Get It

Introduction: T-PLL is a rare, aggressive malignancy with poor prognosis and limited therapies. Outside of prospective trials utilizing alemtuzumab, data is derived primarily from small retrospective series, and limited data on survival outcomes and therapeutic efficacy, particularly beyond frontline therapy are available. In this large multi-center series, with comprehensive clinical data, we evaluated survival and therapeutic outcomes in T-PLL patients, with a focus on identification of prognostic subgroups of T-PLL, that will inform future investigations into the biology and treatment of this disease. Methods: We retrospectively evaluated all patients diagnosed with T-PLL at 15 academic cancer centers throughout the USA between 2000-2023 using the recent TPLL-ISG staging and response criteria with overall response rate (ORR) defined as CR and PR. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier methods and cox proportional hazard models. Single-cell RNA sequencing (scRNAseq) was performed using the standard 10X Genomics platform. Results: 377 patients, with a median follow-up time of 29 months (range: 0-196) were evaluated. The median age at diagnosis was 64 and 51% were male. In evaluated patients (n=223), TCL1A was positive by cytogenetics or FISH in 82%. 61% of patients had CD4+CD8- T-PLL, 11% of patients had CD4-CD8+ T-PLL, and 24% of patients had CD4+CD8+ T-PLL, with 4% unknown. 175 patients (46.4%) had known nodal involvement at diagnosis identified by PET or CT scan. Among treated patients (n=342, 91%), using TPLL-ISG criteria, the ORR to any frontline treatment was 67% (49% CR, 18% PR). Median OS and PFS was 19 months and 10 months in responding patients from the start of treatment initiation. For those treated with frontline alemtuzumab (n=250), the ORR was 74% (58% CR), with a median OS and PFS of 18 and 12 months. 20 patients (5%) were treated with a combination of alemtuzumab/pentostatin frontline with an ORR of 85% (70% CR), which was superior to alemtuzumab alone (ORR 74%, 58% CR). Patients that had frontline chemotherapy (excluding pentostatin, n=48) had a worse ORR of 35% (15% CR) (p&lt;0.001), and a worse PFS of 4 months (p=0.002), when compared to those who received alemtuzumab. Among patients in 1st CR/PR (n=226), 44% (n=99) received an allograft and had an improved 3-year OS of 50% vs 17%, (HR=0.67, 95%CI 0.48-0.93), and 50% improvement in PFS (HR 0.48, 0.33-0.68) compared to those who did not receive an allograft. For patients that received second line treatment (n=176, 52%), re-treatment with alemtuzumab (n=33) produced a 46% ORR (21% CR). Other active second-line treatments included: pentostatin (n=23; 44% ORR, 17% CR), ruxolitinib-based regimens (n=4; 25% ORR, 0% CR), venetoclax-based regimens (n=13; 39% ORR, 8% CR), bendamustine (n=10; 30% ORR, 0% CR), and nelarabine (n=4; 75% ORR, 50% CR). In subgroup survival analysis, TCL1A+ patients had a worse OS and PFS when compared to TCL1A- patients (23 months vs 43 months; p=0.02), and (14 months vs 24 months; p=0.02) respectively, with HR 1.58 (1.08, 2.31) (p=0.02) for OS and HR 1.62 (1.09-2.40) (p=0.02) for PFS. Furthermore, CD4- T-PLL had worse OS (16 months vs 25 months) when compared to CD4+ patients [HR 1.57 (1.08, 2.27), p=0.02]. Single cell RNA seq in 13 patients, including 3 TCL1A- patients, with a total of 66,269 T-PLL cells, demonstrated a unique RNA signature between the CD4+/- and TCL1A+/- patients, suggesting these represent unique molecular subtypes of T-PLL. Conclusions: In this large, multi-center study of T-PLL, frontline treatment with a combination of alemtuzumab/pentostatin improved response rates and OS. Further, among patients who attained a CR, allograft improved OS & PFS vs no allograft. In relapsed T-PLL, retreatment with alemtuzumab had a high ORR, and we report significant activity of multiple novel/alternative agents with the largest reported numbers to date. Intriguingly, TCL1A+, and CD4- T- PLL had worse OS/PFS, and scRNAseq confirmed unique molecular signatures in these populations, suggesting these represent novel molecular subtypes of T-PLL with prognostic significance. These studies form the foundation for future, targeted, therapeutic studies in this rare, aggressive disease with few treatment options.
Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
Ansell, Stephen M. , Scott, David W. , Mehta–Shah, Neha , Amengual, Jennifer E. , Cole, Peter D. , Forlenza, Christopher J. , Jegede, Opeyemi A. , Steidl, Christian , Natkunam, Yasodha , Kahl, Brad S. , Diefenbach, Catherine

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4427-4427

10.1182/blood-2024-201624 Get It

Background: The Phase 1/2 ECOG-ACRIN sponsored intergroup trial E4412 (NCT01896999) investigated brentuximab vedotin (BV) combined with the checkpoint inhibitors nivolumab (N) and ipilimumab (I) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R HL). Here we present the safety and efficacy results for the cohort of pediatric patients aged 12-17 years. Methods: Patients were randomly assigned to treatment with the doublet of BV/N or triplet of BV/N/I, with the following dosing: BV 1.8mg/kg every 21 days for up to 16 cycles; Nivolumab 3mg/mg every 21 days for up to 34 cycles; Ipilimumab 1mg/kg every 9 weeks for up to 9 doses. Response evaluation by PET/CT was performed after 4 cycles. Transplant-eligible patients with CR could discontinue protocol therapy to receive a consolidative autologous stem cell transplant (ASCT). Results: Sixteen pediatric patients with a median age of 16 (range 12-17) were randomized. 75% of patients had received only 1 prior line of treatment with none having previously received BV and only 1 patient with prior ASCT. All patients were treated (8 in each arm) and included in the pediatric safety analysis cohort receiving at least one cycle of therapy. There were four reported grade (gr) 3 or greater toxicities: lymphopenia (gr 3) and neutropenia (gr 3) on the BV/N arm; and neutropenia (gr 4) and rash (gr 3) on the BV/N/I arm. Rash of any grade was more common in patients treated with BV/N/I (n=6) compared to BV/N (n=1). Peripheral sensory neuropathy was reported in 2 patients (BV/N, gr 2, n=2) There were no grade 5 toxicities. Fourteen patients (7 in each arm) were evaluable for response. The CR rate on both the BV/N and BV/N/I arms was 100%. The median survival follow up was 23.7 months (15.7 - 31.7). The 24-month PFS was 57% for BV/N and 100% for BV/N/I. Six patients (2 BV/N; 4 BV/N/I) discontinued protocol therapy to receive a consolidative ASCT. The 24-month PFS for patients consolidated with an ASCT was 100%, with all events occurring in patients randomized to BV/N, but not receiving an ASCT. Conclusion: Pediatric patients receiving both BV/N and BV/N/I had 100% CR rate with limited toxicity. Although this is a small cohort, there have been no progression events observed in patients treated with BV/N/I, including 3 patients treated without a consolidative ASCT.
Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)
Alencar, Alvaro J. , Mehta-Shah, Neha, Lu‐Emerson, Christine , Rutherford, Sarah C. , Dockter, Travis , Geyer, Susan M. , Fuente, Macarena de la, Dinner, Shira, Rubenstein, James L. , Leonard, John P. , Bobek, Olivia , Mehta–Shah, Neha , Epperla, Narendranath , Olszewski, Adam J. , Ollila, Thomas A , Singer, Samuel , Rosenstein, Lori J. , Hsi, Eric D. , Bartlett, Nancy L.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4502.4-4502.4

10.1182/blood-2024-209238 Get It

Background: The rising incidence of PCNSL in the elderly represents an unmet need with an undefined standard approach [Villano Br J Cancer 2011]. High-dose methotrexate-based (HD-MTX) therapy is feasible and effective in older patients, but outcomes in this population remain poor. Despite high response rates to HD-MTX induction therapy, poor candidacy for intensive consolidative therapy results in transient disease control that may benefit from maintenance strategies [David Am J Hematol 2023]. Lenalidomide (len) has demonstrated activity in PCNSL even at low doses and represents a potential alternative to consolidation considering its extensive use in maintenance settings [Vu Br J Haematol 2019]. Anecdotal activity in PCNSL by checkpoint inhibitors such as nivolumab (nivo) has been reported [Nayak Blood 2017], and its immune response may be enhanced by len [Görgün Clin Cancer Res 2015]. A051901 evaluates the feasibility of the addition of len and nivo to rituximab (R) and HD-MTX as first line induction therapy followed by len-nivo maintenance in elderly patients with PCNSL not eligible for intensive consolidation. Study Design and Methods: This is a single-arm phase 1 multicenter US study (NCT04609046) conducted by the Alliance for Clinical Trials in Oncology with a traditional 3+3 design. Eligible patients are 18 years of age or older with untreated diffuse large B-cell lymphoma PCNSL diagnosed through brain biopsy or resection, or cerebrospinal (CSF) or vitreous fluid not considered candidates for high dose chemotherapy consolidation. This study is available to all eligible patients, regardless of race, gender, or ethnic origin. Patients must have adequate end-organ function including creatinine clearance of at least 50 mL/min. Use of systemic corticosteroids for disease control to be tapered after initiation of therapy is allowed. Induction consists of six 14-day cycles with rituximab 500 mg/m2 i.v. on day 1, HD-MTX 3g/m2 i.v. on day 2. In the most recent treatment schedule, a 5-day course of lenalidomide PO at different dose levels (dose level (DL) 1 = 10 mg, DL2 = 15 mg, DL3 = 20 mg) is initiated immediately after adequate clearance of HD-MTX. Once a maximum tolerated dose (MTD) of len is defined, a subsequent cohort will evaluate the addition of nivo 240 mg i.v. to the day 14 of the induction cycle of R-HD-MTX plus len at the MTD. Patients who present any clinical benefit from induction with at least stable disease by International PCNSL Collaborative Group response criteria are eligible for maintenance - twelve 28-day cycles of therapy with len 15 mg PO from day 1 to day 21 (regardless of dose during induction) +/- nivo 480 mg i.v. on day 1 (for those who received len and nivo during induction). The primary endpoint of the induction therapy is the MTD of len when given in combination with R-HD-MTX; the primary endpoint of maintenance is its feasibility, defined as the proportion of patients able to remain on maintenance for at least 6 cycles. As of July 2024, 16 patients have been enrolled with a maximum expected sample size of 47 patients with the assumption of 75% of patients being eligible to proceed with maintenance and 50% of those who begin maintenance not progressing in the first 6 cycles. Overall response, adverse events, progression-free and overall survival will be evaluated in all eligible patients with a focus on the outcome of patients treated at the MTD. For patients who consent to biobanking, diagnostic tissue, peripheral blood and CSF from different timepoints are collected and banked with planned exploratory analyses including whole exome sequencing, circulating tumor DNA, proteomics, metabolomics. Support: U10CA180821, U10CA180882. https://acknowledgments.alliancefound.org.
Medially Migrating Vestibular Schwannomas: A Review of 10 Cases
Brovold, Brooklyn L., Lohse, Christine M. , Lane, John I. , Breen, Joseph J., Carlson, Matthew L., Breen, Joseph L, Mehta, P. , Bathla, Girish , Breen, Joseph L., Gompel, Jamie J. Van , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | December 4, 2024 | Volume: 46 | Issue: 1 | Pages: e41-e45

10.1097/mao.0000000000004381 | PMID 39627846 Get It

Objective To analyze cases of medial migration of vestibular schwannomas to propose an underlying mechanism. Study Design Retrospective chart review. Patients Ten patients from one institution with sporadic vestibular schwannomas that demonstrated medial migration toward the cerebellopontine angle on serial imaging were reviewed. Interventions Among the 10 patients studied, 8 patients underwent stereotactic radiosurgery and 2 were managed with wait-and-scan. All serial imaging was analyzed throughout follow-up. Main Outcome Measures Volumetric and linear measurements were used to assess vestibular schwannoma growth. The fundal fluid cap length was measured from the most lateral end of the neoplasm within the internal auditory canal to the medial end of the cochlea. Pure tone averages of 0.5, 1, 2, and 3 kHz, word recognition scores, and AAO-HNS hearing class were used to assess levels of hearing loss per patient. Results Tumor growth exhibited a positive correlation with medial migration. Of the 10 patients studied, 9 exhibited tumor volume growth from initial to most recent imaging. Median changes in tumor volumes and fundal fluid cap lengths from initial diagnosis to the most recent imaging regardless of intervention were 130 mm3 (range 1,400–2,970) and 2.8 mm (range 1.8–6.0), respectively. Migration was noted in 4 patients prior to any intervention, in 4 patients postradiosurgery, and in 2 patients before and after radiosurgery. Therefore, half of the tumors studied migrated before an intervention and half migrated postradiosurgery. No correlation of migration and hearing decline was observed. Conclusion Medial migration of vestibular schwannoma is associated with an increase in tumor volume, supporting a “tumor squeeze” mechanism within a conical internal auditory canal toward the wider porus acusticus and cerebellopontine angle.
Weight Loss in Parkinson’s Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth
DiBaise, John K. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Hoffman‐Snyder, Charlene , Lin, Tanya, Driver-Dunckley, Erika, Hoffman-Snyder, Charlene, Crowell, Michael D. , Adler, Charles H.

Mayo Clinic

Journal of Parkinson’s Disease | November 26, 2024 | Volume: 8 | Issue: 4 | Pages: 571-581

10.3233/jpd-181386 | PMID 30149465 Get It

Background and Objective: Weight loss and small intestinal bacterial overgrowth (SIBO) are common in Parkinson’s disease (PD). We aimed to study the relationship between weight loss and SIBO in PD. Methods: This was a cross-sectional study with a prospective, interventional component. Consecutive patients seen in the PD clinic who agreed to participate underwent extensive history, movement exam, SIBO breath testing and answered questionnaires. A subset of those in the weight loss group were treated with rifaximin for 14 days and returned 3 months later for an assessment of their weight, GI symptoms, quality of life and SIBO status. All analyses were adjusted for age and disease duration. Results: Fifty-one patients participated in the study; 37 without weight loss and 14 with weight loss. Total energy intake including the distribution of macronutrient intake was similar between groups while physical activity was less in those with weight loss. PD severity scores did not differ between groups; however, PD-specific quality of life scores were significantly worse for the summary index and the subscales of emotional well-being, social support and communication. The prevalence of constipation, dyspepsia and abdominal pain/discomfort was higher in those with weight loss. The prevalence of SIBO was 14% in the weight loss group and was not different between groups. Eight PD patients with weight loss were treated with rifaximin; no significant change in GI symptoms, quality of life or weight was seen 3 months later. Conclusion: Although a number of differences were identified in quality of life and gastrointestinal symptoms between groups with and without weight loss, SIBO was not associated with weight loss in patients with PD. Given the exploratory nature and small number of patients with weight loss, however, further study is suggested.
Nomophobia: a challenge among healthcare professionals in Africa
Lakhani, Shan , Mbithi, Annastacia , Gandhi, Zainab , Mehta, Priyal , Kashyap, Rahul , Kashyap, Rahul , Shah, Reena , Shah, Jasmit , Singh, Aakanksha , Surani, Salim

Mayo Clinic

Hospital Practice | November 25, 2024 | Volume: 53 | Issue: 1 | Pages: No page available

10.1080/21548331.2024.2432858 | PMID 39582129 Get It

LTBK-07. PROGRESSION-FREE AND OVERALL SURVIVAL RESULTS OF ECOG-ACRIN E3F05: A PHASE 3 INTERGROUP TRIAL OF RADIATION ± TEMOZOLOMIDE FOR GRADE II GLIOMAS
Schiff, David , O’Neill, Anne, Brown, Paul D. , Jenkins, Robert B. , Youssef, Emad, Uhm, Joon H. , Giglio, Pierre , Cavaliere, Robert , Ashby, Lynn S., Kleinberg, Lawrence , Schiff, David, Mehta, Minesh P. , Giannini, Caterina , Suh, John H. , Moots, Paul L

Mayo Clinic

Neuro-Oncology | November 23, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii2

10.1093/neuonc/noae165.1303 Get It

Abstract BACKGROUND Both radiation and temozolomide (TMZ) have meaningful single-modality anti-tumor activity against low-grade gliomas. ECOG-ACRIN E3F05 tested whether combined therapy with radiation and temozolomide is more effective than radiation alone in patients with grade II gliomas. METHODS Patients with grade II gliomas (central pathology review performed post hoc), no prior radiation/chemotherapy, and either age &gt; 40, uncontrolled symptoms/seizures, or progression after initial observation were randomized 1:1 to radiation 50.4 Gy alone in 28 fractions (Arm A) versus radiation 50.4 Gy with concomitant and 12 four-week cycles of post-radiation TMZ (Arm B). Randomization was stratified by 1p/19q codeletion status, age, KPS, pre-operative tumor diameter, and contrast enhancement. The primary endpoint was progression-free survival (PFS); overall survival (OS), quality of life, cognition, severe toxicities, and impact of codeletion status were secondary objectives. RESULTS The trial opened 1/09. Accrual was stopped in 1/14 after RTOG 9802 reported benefit from the addition of PCV chemotherapy to radiation in grade II gliomas. A total of 172 subjects were enrolled. Median age was 44 (range 19-78) and 54% male. 1p/19q codeletion was present in 44%. NCI CTCAE (version 4) grade 3+ toxicity was more common in participants treated with TMZ: thrombocytopenia (11%) and neutropenia (5%) versus none in the radiation alone arm. With a median follow-up of 117 months, OS was superior in Arm B (HR 0.54, 95% CI 0.31-0.95, stratified log-rank p value 0.03). OS HRs were 0.56 and 0.53 for subjects with and without 1p/19q codeleted tumors, respectively. PFS did not differ between Arms A and B (HR 0.76, 95% CI 0.44-1.28, p = 0.30). Five and ten-year OS were 78% and 70% in Arm B versus 70% and 47% in Arm A. CONCLUSION The addition of temozolomide to radiation improves overall survival in both co-deleted and non-co-deleted grade II gliomas.
The herpes simplex virus alkaline nuclease is required to maintain replication fork progression
Mullon, Patrick J. , Maldonado-Luevano, Emiliano, Mehta, Kavi P.M. , Mohni, Kareem N.

Mayo Clinic

Journal of Virology | November 7, 2024 | Volume: 98 | Issue: 12 | Pages: No page available

10.1128/jvi.01836-24 | PMID 39508568 Get It

ABSTRACT Herpes simplex virus is a large double-strand DNA virus that replicates in the nucleus of the host cell and interacts with host DNA replication and repair proteins. The viral 5′ to 3′ alkaline nuclease, UL12, is required for production of DNA that can be packaged into infectious virus. The UL12-deleted virus, AN-1, exhibits near wild-type levels of viral DNA replication, but the DNA cannot be packaged into capsids, suggesting it is structurally aberrant. To better understand the DNA replication defect observed in AN-1, we utilized isolation of proteins on nascent DNA (iPOND), a powerful tool to study all the proteins at a DNA replication fork. Combining iPOND with stable isotope labeling of amino acids in cell culture (SILAC) allows for a quantitative assessment of protein abundance when comparing wild type to mutant replication forks. We performed five replicates of iPOND-SILAC comparing AN-1 to the wild-type virus, KOS. We observed 60 proteins that were significantly lost from AN-1 forks out of over 1,000 quantified proteins. These proteins largely represent host DNA replication proteins including MCM2-7, RFC1-5, MSH2/6, MRN, and proliferating cell nuclear antigen. These observations are reminiscent of how these proteins behave at stalled human replication forks. We also observed similar protein changes when we stalled KOS forks with hydroxyurea. Additionally, we observed a decrease in the rate of AN-1 replication fork progression at the single-molecule level. These data indicate that UL12 is required for DNA replication fork progression and that forks stall in the absence of UL12. IMPORTANCE Herpes simplex virus 1 (HSV-1) is a near-ubiquitous pathogen within the global population, causing a lifelong latent infection with sporadic reactivation throughout the life of the host. Within at-risk and immunocompromised communities, HSV-1 infection can cause serious morbidities including herpes keratitis and encephalitis. With the possibility of herpesviruses to evade established antiviral therapies and there being no approved HSV-1 vaccine, there comes a need to investigate potential targets for intervention against infection and subsequent disease. UL12 is the viral 5'–3' exonuclease, which is required for the production of infectious progeny. In this study, we show that in the absence of UL12, viral replication fork progression is abrogated. These data point to UL12 as an attractive target for intervention, which could lead to better clinical outcomes of HSV-1-associated disease in the future.
Predicting Post‐Mortem α‐Synuclein Pathology by the Combined Presence of Probable REM sleep behavior disorder and Hyposmia
Tremblay, Cécilia , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Choudhury, Parichita , Belden, Christine M. , Lee‐Iannotti, Joyce , Beach, Thomas G. , Mehta, Shyamal, Beach, Thomas G , Adler, C H , Choudhury, Parichita , Driver‐Dunckley, Erika , Shprecher, David , Atri, Alireza , Serrano, Geidy E.

Mayo Clinic

Movement Disorders Clinical Practice | November 5, 2024 | Volume: 12 | Issue: 2 | Pages: 157-165

10.1002/mdc3.14244 | PMID 39499184 Get It

AbstractBackgroundIdiopathic rapid eye movement sleep behavior disorder (RBD) is a strong known predictor of a final clinicopathological diagnosis of a Lewy type α‐synucleinopathy (LTS). Olfactory dysfunction is an early symptom of synucleinopathies and has been repeatedly associated with the presence of post‐mortem LTS.ObjectiveTo assess the combined value of a clinician diagnosis of probable RBD (PRBD) and hyposmia in predicting the post‐mortem presence of LTS in a broader, less‐selected, volunteer elderly population.MethodsWe studied 652 autopsied subjects from the Arizona Study of Aging and Neurodegenerative Disorders, which were evaluated for PRBD, had completed annual movement and cognitive assessments, and had at least one the University of Pennsylvania Smell Identification Test (UPSIT) olfactory test.ResultsHistological evidence of LTS was significantly more frequent in those who had PRBD (112/152: 73.7%) than those without (177/494: 35.8%) (P < 0.001). LTS was more frequent in cases with PRBD and a low UPSIT score (90.8%) compared to cases with PRBD only (73.7%) (P < 0.001) or cases with a low UPSIT score only (69.4%) (P < 0.001). Sensitivity of PRBD diagnosis for predicting LTS was 38.8% and specificity 88.8%, whereas sensitivity of a low UPSIT score was 74.4% and specificity 73.4% (Youden's index = 0.276 for PRBD, 0.478 for UPSIT). When combining both measures, sensitivity was 34.3% and specificity increased to 97.2%.ConclusionPRBD, diagnosed without sleep study confirmation, combined with a reduced olfactory performance is highly specific for predicting post‐mortem presence of LTS. The combination of both measures may provide a cost‐effective means of predicting LTS in a broader community.